Trial Information

Summary: Pharmacokinetics of Efavirenz During Treatment of HIV-1 Infected Subjects with Hepatic Impairment

The purpose of this study is to show the safety of Efavirenz (Sustiva) in HIV-1 infected patients as well as to see how it works in the body. Patients may qualify for participation in this study if they are currently taking Efavirenz.
There will be 1 clinic visit as well as a 2 overnight stay at Mount Sinai. All tests and procedures will be provided at no cost and there will be reimbursement for time and travel expenses.
Compensation Provided

Patient Inclusion/Exclusion Criteria:

You may be eligible to participate if you
-are male or female at least 18 years old
-are HIV positive
-are currently taking Efavirenz (Sustiva) for your HIV
-meet additional criteria

You will not be able to participate if you
-are pregnant or breastfeeding
-have a history of coronary heart disease or congestive heart failure
-smoke more than 1 pack of cigarettes a day
-have had a hepatitis flare-up in the last 6 months

If you would like to learn more about participating in this study, please send an e-mail message using the form below.